1Who Are the Special Populations?

FThe two reference candidates, and everyone else

Classic adult candidacy was framed around bilateral severe-to-profound loss with little open-set speech understanding, and classic paediatric candidacy around the congenitally deaf infant implanted early to exploit cortical plasticity. Special populations are defined by what they do NOT share with those references: they may have usable hearing in one or both ears, a single deaf ear, a lesion at the synapse or nerve rather than the hair cell, or an age at the far ends of the lifespan. The shared analytic move for every atypical group is to ask what the standard criteria were really proxies for: enough surviving neural substrate to stimulate, enough central capacity to learn, and a realistic gap between current function and expected implant benefit. Because these groups were historically excluded, much of the evidence base is younger and thinner than for the reference candidate, which raises the weight placed on individual work-up and counselling. Other chapters cover the candidacy test battery and conventional indications; this chapter deliberately addresses the patients who sit outside those defaults.[2009][2020][2014]

FWhy the standard criteria bend

Audiometric cut-offs assume the audiogram reflects the lesion, but in auditory neuropathy spectrum disorder speech understanding is far worse than the pure-tone average predicts, so a threshold-based rule misclassifies the patient. In single-sided deafness the better ear is normal or near-normal, so the patient fails every traditional bilateral criterion yet still lacks binaural hearing, spatial cues, and often suffers disabling tinnitus. Expected outcome, not just the audiogram, drives modern decisions: a long duration of profound deafness in the ear to be implanted predicts poorer benefit and is increasingly weighed alongside threshold data. Counselling targets shift with the group: an SSD adult is counselled toward localisation, listening in noise, and tinnitus relief rather than telephone speech, while a family of an ANSD infant is counselled about diagnostic uncertainty and the central role of imaging. Outcome variance is wider in atypical groups, so the same procedure can yield a transformative result or near-rejection of the device depending on the underlying biology.[2020][2013][2013]

TCandidacy as a moving frontier

Each expansion followed the same pattern: a group once considered ineligible was implanted, outcomes were measured, and the indication formally widened, usually with regulatory approval lagging clinical practice by years. Residual low-frequency hearing was once a contraindication; hearing-preservation surgery and electric-acoustic stimulation turned it into an asset, allowing implantation of patients with substantial usable acoustic hearing. Single-sided and asymmetric hearing loss moved from off-label experimentation to a U.S. FDA-approved indication in July 2019. Age limits have stretched in both directions: paediatric implantation is now routinely performed within the first year of life, while healthy octogenarians and nonagenarians are implanted when central capacity and motivation are adequate. Complex ears once deemed impossible, including ossified cochleae after meningitis and malformed inner ears, are now implanted with tailored arrays and approaches. The frontier metaphor matters clinically: a patient declined a decade ago may be a candidate today, so periodic re-evaluation is part of good practice.[2014][2017][2020]

CIndividualised goals and honest counselling as the common thread

For atypical candidates the success metric must be defined before surgery and personalised: tinnitus relief and localisation for SSD, language access for a young ANSD child, or independent living and communication for an elderly recipient. Honest counselling means quantifying uncertainty rather than hiding it, including the real possibility of limited benefit when the cochlear nerve is deficient or the duration of deafness is long. A motivated, well-informed patient who values daily device use is itself a favourable prognostic factor, particularly in SSD where non-use is a recognised failure mode. Multidisciplinary input, including imaging review, genetics, and where relevant developmental assessment, replaces a single audiometric gate for these groups. The unifying clinical stance is that the implant is offered as the best available option for that individual's specific deficit, with outcomes framed as a probability distribution rather than a promise.[2020][2010][2013]